A 7-Week, Randomized, Double-Blind Trial of Olanzapine/Fluoxetine Combination Versus Lamotrigine in the Treatment of Bipolar I Depression
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Determine the efficacy and tolerability of olanzapine/fluoxetine combination (OFC) for treatment of acute bipolar I depression compared with lamotrigine. METHOD: The 7-week, acute phase of a randomized, double-blind study compared OFC (6/25, 6/50, 12/25, or 12/50 mg/day; N = 205) with lamotrigine ([LMG] titrated to 200 mg/day; N = 205) in patients with DSM-IV-diagnosed bipolar I disorder, depressed. The study was conducted from November 2003 to August 2004. RESULTS: Completion rates were similar between treatments (OFC, 66.8% vs. LMG, 65.4%; p = .835). OFC-treated patients had significantly greater improvement than lamotrigine-treated patients in change from baseline across the 7-week treatment period on the Clinical Global Impressions-Severity of Illness scale (primary outcome) (p = .002, effect size = 0.26), Montgomery-Asberg Depression Rating Scale (MADRS) (p = .002, effect size = 0.24), and Young Mania Rating Scale total scores (p = .001, effect size = 0.24). Response rates did not significantly differ between groups when defined as > or = 50% reduction in MADRS score (OFC, 68.8% vs. LMG, 59.7%; p = .073). Time to response was significantly shorter for OFC-treated patients (median days [95% CI] = OFC, 17 [14 to 22] vs. LMG, 23 [21 to 34]; p = .010). There was a significant difference in incidence of "suicidal and self-injurious behavior" adverse events (OFC, 0.5% vs. LMG, 3.4%; p = .037). Somnolence, increased appetite, dry mouth, sedation, weight gain, and tremor occurred more frequently (p < .05) in OFC-treated patients than lamotrigine-treated patients. Weight, total cholesterol, and triglyceride levels were significantly elevated in OFC-treated patients compared with lamotrigine-treated patients (all p < or = .001). CONCLUSIONS: Patients with acute bipolar I depression had statistically significantly greater improvement in depressive and manic symptoms, more treatment-emergent adverse events, greater weight gain, and some elevated metabolic factors with OFC than lamotrigine. Treatment differences were of modest size.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Olanzapine‐fluoxetine combination (level 2)264, 265 is effective and is also recommended as a second‐line option.”
Citations
Cites
Still being checked.
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Conflicts of interest: none declared
Suga, H., Eto, H., Inoue, K., Aoi, N., Kato, H., Araki, J., Higashino, T., Yoshimura, K., Yoshimura, K., Publication, A. F., et al. (2009) · Oxford University Press eBooks · doi:10.1093/med/9780198719021.002.0007 · Cited by 442
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
“Its effi cacy is supported by one placebocontrolled trial (Tohen et al. 2003) and one head-tohead comparison to lamotrigine (Brown et al. 2006) (CE B, RG 3).”
BackgroundResultInfluentialLoebel, A., Cucchiaro, J., Silva, R., Kroger, H., Sarma, K., Xu, J., & Calabrese, J. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070985 · Cited by 293
Pharmacological treatment of adult bipolar disorder
Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0044-2 · Cited by 272
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S. V., MacQueen, G., McIntyre, R. S., Sharma, V., Beaulieu, S., & for CANMAT guidelines group (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00432.x · Cited by 264
The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments
Machado-Vieira, R., Baumann, J., Wheeler-Castillo, C., Latov, D., Henter, I. D., Salvadore, G., & Zarate, C. A. (2010) · Pharmaceuticals · doi:10.3390/ph3010019 · Cited by 263
“The combination of fluoxetine and the atypical antipsychotic olanzapine has proven to be useful for achieving antidepressant response in both MDD and bipolar depression [48–50].”
BackgroundBipolar disorder—focus on bipolar II disorder and mixed depression
Benazzi, F. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60453-x · Cited by 231
Bipolar depression: a major unsolved challenge
Baldessarini, R. J., Vázquez, G. H., & Tondo, L. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0160-1 · Cited by 235
Berk, M., Brnabic, A., Dodd, S., Kelin, K., Tohen, M., Malhi, G. S., Berk, L., Conus, P., & McGorry, P. D. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00889.x · Cited by 188
Self-citationTreatment of bipolar disorder: a systematic review of available data and clinical perspectives
Fountoulakis, K. N., & Vieta, E. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009231 · Cited by 169
Weight gain in bipolar disorder: pharmacological treatment as a contributing factor
Torrent, C., Amann, B., Sánchez‐Moreno, J., Colom, F., Reinares, M., Comes, M., Rosa, A. R., Scott, J., & Vieta, E. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01204.x · Cited by 169
New treatment guidelines for acute bipolar depression: A systematic review
Nivoli, A. M. A., Colom, F., Murru, A., Pacchiarotti, I., Castro-Loli, P., González-Pinto, A., Fountoulakis, K. N., & Vieta, E. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.05.018 · Cited by 161
Bipolar Depression: Overview and Commentary
Baldessarini, R. J., Vieta, E., Calabrese, J. R., Tohen, M., & Bowden, C. L. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673221003747955 · Cited by 156
Self-citationBipolar II Disorder: Epidemiology, Diagnosis and Management
Benazzi, F. (2007) · CNS Drugs · doi:10.2165/00023210-200721090-00003 · Cited by 179
Grunze, H. (2011) · FOCUS: The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.9.4.500 · Cited by 149
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry
Fountoulakis, K. Ν., Kasper, S. F., Andreassen, O. A., Blier, P., Okasha, A., Severus, E., Versiani, M., Tandon, R., Möller, H., & Vieta, E. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0323-x · Cited by 149
Detke, H. C., DelBello, M. P., Landry, J., & Usher, R. W. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.12.012 · Cited by 135
Selle, V., Schalkwijk, S., Vázquez, G., & Baldessarini, R. (2014) · Pharmacopsychiatry · doi:10.1055/s-0033-1363258 · Cited by 128
Taylor, D. M., Cornelius, V., Smith, L., & Young, A. H. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12343 · Cited by 122
Treatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials
Vieta, E., Locklear, J., Günther, O., Ekman, M., Miltenburger, C., Chatterton, M. L., Åström, M., & Paulsson, B. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181f15849 · Cited by 119
Fountoulakis, K. N., Yatham, L., Grunze, H., Vieta, E., Young, A., Blier, P., Kasper, S., & Moeller, H. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw100 · Cited by 116
Pharmacological Management of Bipolar Depression: Acute Treatment, Maintenance, and Prophylaxis
Vieta, E., & Valentí, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0073-y · Cited by 106
De Fruyt, J., Deschepper, E., Audenaert, K., Constant, E., Floris, M., Pitchot, W., Sienaert, P., Souery, D., & Claes, S. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111408461 · Cited by 95
Overview of antidepressant treatment of bipolar depression
Vázquez, G. H., Tondo, L., Undurraga, J., & Baldessarini, R. J. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000023 · Cited by 94
Atypical antipsychotics in bipolar disorder: systematic review of randomised trials
Derry, S., & Moore, R. A. (2007) · BMC Psychiatry · doi:10.1186/1471-244x-7-40 · Cited by 93
Treatment of bipolar depression: An update
Fountoulakis, K. Ν., Grunze, H., Panagiotidis, P., & Kaprinis, G. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.10.016 · Cited by 93
Treatment‐resistant bipolar depression: towards a new definition
Pacchiarotti, I., Mazzarini, L., Colom, F., Sanchez‐Moreno, J., Girardi, P., Kotzalidis, G. D., & Vieta, E. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01471.x · Cited by 74
Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder
Fountoulakis, K. N., Vieta, E., Siamouli, M., Valenti, M., Magiria, S., Oral, T., Fresno, D., Giannakopoulos, P., & Kaprinis, G. S. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-27 · Cited by 76
“Olanzapine has the highest number of published randomized control trials (RCTs) [1,60,85,87,108-128] and a solid basis supporting its use in bipolar disorder [129],”
Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression
Brown, E., Dunner, D. L., McElroy, S. L., Keck, P. E., Adams, D. H., Degenhardt, E., Tohen, M., & Houston, J. P. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009735 · Cited by 73
“The results of the first 7 wk of the trial (acute phase) have previously been reported (Brown et al. 2006).”
BackgroundMethodResultInfluentialSelf-citationNontricyclic Antidepressants: Predictors of Nonadherence
Brook, O. H., van Hout, H. P. J., Stalman, W. A. B., & de Haan, M. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000246217.34024.53 · Cited by 69
The primacy of mania: A reconsideration of mood disorders
Koukopoulos, A., & Ghaemi, S. N. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2008.07.006 · Cited by 84
Managing the side effects associated with commonly used treatments for bipolar depression
Kemp, D. E. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70007-2 · Cited by 62
Solmi, M., Veronese, N., Zaninotto, L., van der Loos, M. L. M., Gao, K., Schaffer, A., Reis, C., Normann, C., Anghelescu, I.-G., & Correll, C. U. (2016) · CNS Spectrums · doi:10.1017/s1092852916000523 · Cited by 69
Suppes, T., Kroger, H., Pikalov, A., & Loebel, A. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.03.012 · Cited by 65
Anticonvulsants in bipolar disorders: current research and practice and future directions
Bowden, C. L. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00708.x · Cited by 72
Antipsychotic agents in the treatment of bipolar mania
Tohen, M., & Vieta, E. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00710.x · Cited by 62
Self-citationOlanzapine: review of safety 2008
Kantrowitz, J. T., & Citrome, L. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740330802423234 · Cited by 67
Reviewing the diagnostic validity and utility of mixed depression (depressive mixed states)
Benazzi, F. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2007.07.003 · Cited by 58
Anticonvulsants in bipolar disorder
Grunze, H. (2010) · Journal of Mental Health · doi:10.3109/09638230903469186 · Cited by 66
The effectiveness of anticonvulsants in psychiatric disorders
Grunze, H. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.1/hcrgrunze · Cited by 67
A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression
Reinares, M., Rosa, A. R., Franco, C., Goikolea, J. M., Fountoulakis, K., Siamouli, M., Gonda, X., Frangou, S., & Vieta, E. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000491 · Cited by 56
Van Lieshout, R. J., & MacQueen, G. M. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.057612 · Cited by 57
Tamayo, J. M., Zarate, C. A., Vieta, E., Vázquez, G. H., & Tohen, M. F. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709991246 · Cited by 57
Self-citationMedicating mood with maintenance in mind: bipolar depression pharmacotherapy
Malhi, G. S., Adams, D., & Berk, M. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00711.x · Cited by 59
Self-citationMalhi, G. S., Adams, D., Cahill, C. M., Dodd, S., & Berk, M. (2009) · Drugs · doi:10.2165/11318850-000000000-00000 · Cited by 64
Self-citationAn update of evidence-based treatment of bipolar depression: where do we stand?
Fountoulakis, K. Ν. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328333e132 · Cited by 57
Besag, F., Vasey, M. J., Sharma, A., & Lam, I. C. H. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211045870 · Cited by 62
Receptor targets for antidepressant therapy in bipolar disorder: An overview
Fountoulakis, K. Ν., Kelsoe, J. R., & Akiskal, H. S. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.04.043 · Cited by 54
Baghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Goodwin, G. M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Malt, U. F., Stein, D. J., et al. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0259-6 · Cited by 57
Kasper, S. F., Calabrese, J. R., Johnson, G., Tajima, O., Vieta, E., Viguera, A. C., Yatham, L. N., & Young, A. H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n1014 · Cited by 59
Treatment options for acute depression in bipolar disorder
Bauer, M., Ritter, P., Grunze, H., & Pfennig, A. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2012.00991.x · Cited by 49
Risk of a lamotrigine-related skin rash: Current meta-analysis and postmarketing cohort analysis
Wang, X.-Q., Xiong, J., Xu, W., Yu, S., Huang, X., Zhang, J., Tian, C.-L., Huang, D., Jia, W.-Q., & Lang, S.-Y. (2014) · Seizure · doi:10.1016/j.seizure.2014.12.001 · Cited by 50
Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?
Ketter, T. A., Citrome, L., Wang, P. W., Culver, J. L., & Srivastava, S. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01645.x · Cited by 49
Lithium treatment — moderate dose use study (LiTMUS) for bipolar disorder: rationale and design
Nierenberg, A. A., Sylvia, L. G., Leon, A. C., Reilly-Harrington, N. A., Ketter, T. A., Calabrese, J. R., Thase, M. E., Bowden, C. L., Friedman, E. S., Ostacher, M. J., et al. (2009) · Clinical Trials · doi:10.1177/1740774509347399 · Cited by 45
Hamoda, H. M., & Osser, D. N. (2008) · Harvard Review of Psychiatry · doi:10.1080/10673220802277904 · Cited by 47
Two generations of mood stabilizers
Rybakowski, J. K. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570700795x · Cited by 46
Wang, M., Tong, J.-H., Huang, D., Zhu, G., Liang, G.-M., & Hong, D. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3453-1 · Cited by 41
Efficacy and tolerability of treatments for bipolar depression
Vázquez, G. H., Holtzman, J. N., Tondo, L., & Baldessarini, R. J. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.05.016 · Cited by 43
Pharmacotherapy of bipolar depression: An update
Thase, M. E. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0055-6 · Cited by 42
Rubner, P., Koppi, S., & Conca, A. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902838242 · Cited by 39
Review of olanzapine in the management of bipolar disorders
Narasimhan, M., Bruce, T. O., & Masand, P. S. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a932 · Cited by 47
Weisler, R. H., Cutler, A. J., Ballenger, J. C., Post, R. M., & Ketter, T. A. (2006) · CNS Spectrums · doi:10.1017/s1092852900014917 · Cited by 37
Zhang, Y., Yang, H., Yang, S., Liang, W., Dai, P., Wang, C., & Zhang, Y. (2013) · PubMed Central · doi:10.3969/j.issn.1673-5374.2013.31.009 · Cited by 36
Atypical Antipsychotics for the Treatment of Bipolar Disorder: More Shadows than Lights
Gentile, S. (2007) · CNS Drugs · doi:10.2165/00023210-200721050-00002 · Cited by 37
Towards the clinical implementation of pharmacogenetics in bipolar disorder
Salloum, N. C., McCarthy, M. J., Leckband, S. G., & Kelsoe, J. R. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-90 · Cited by 34
Tamayo, J. M., Sutton, V. K., Mattei, M. A., Diaz, B., Jamal, H. H., Vieta, E., Zarate, C. A., Fumero, I., & Tohen, M. F. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181ad223f · Cited by 36
Self-citationLamotrigine: when and where does it act in affective disorders? A systematic review
Amann, B. L., Born, C., Crespo, J. M., Pomarol‐Clotet, E., & McKenna, P. J. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110376695 · Cited by 30
The role of lamotrigine in the management of bipolar disorder
Ng, F., Hallam, K. T., Lucas, N., & Berk, M. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a920 · Cited by 43
The Pharmacological Treatment of Bipolar Disorder: The Question of Modern Advances
Hirschowitz, J., Kolevzon, A., & Garakani, A. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.507042 · Cited by 34
Olanzapine plus fluoxetine for bipolar disorder: A systematic review and meta-analysis
Silva, M. T., Zimmermann, I. R., Galvão, T. F., & Pereira, M. G. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.11.001 · Cited by 32
Oliva, V., Prisco, M. D., Spina, E. L., Paolucci, S., Fico, G., Anmella, G., Hidalgo‐Mazzei, D., Murru, A., Pompili, M., Fornaro, M., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103413 · Cited by 29
Taiwan consensus of pharmacological treatment for bipolar disorder
Bai, Y., Chang, C.-J., Tsai, S., Chen, Y.-C., Hsiao, M., Li, C., Tu, P., Chang, S., Shen, W. W., & Su, T. (2013) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2013.06.013 · Cited by 29
Quetiapine monotherapy for bipolar depression
Thase, M. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s1162 · Cited by 34
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Perlis, R. H. (2007) · PubMed · Cited by 31
Chertkow, Y., Weinreb, O., Youdim, M. B. H., & Silver, H. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0255-4 · Cited by 30
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women
Houston, J., Dharia, S., Bishop, J. R., Ellingrod, V. L., Fijal, B. A., Jacobson, J. G., & Hoffmann, V. P. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.10.020 · Cited by 26
Hu, Y., Zhang, H., Wang, H., Wang, C., Kung, S., & Li, C. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114468 · Cited by 27
The Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 25
Shim, I. H., Woo, Y. S., Kim, M.-D., & Bahk, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112406 · Cited by 26
Olanzapine–fluoxetine combination for the treatment of bipolar depression
Citrome, L. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.632368 · Cited by 22
An overview of pharmacotherapy for bipolar I disorder
Morsel, A., Morrens, M., & Sabbe, B. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1426746 · Cited by 24
Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder
Cheniaux, E., & Nardi, A. E. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1651291 · Cited by 26
Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility
Dodd, S., & Berk, M. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.9.1299 · Cited by 22
Bobo, W. V., & Shelton, R. C. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5819 · Cited by 27
Wang, D., & Osser, D. N. (2019) · Bipolar Disorders · doi:10.1111/bdi.12860 · Cited by 23
Olanzapine/Fluoxetine: A Review of its Use in the Treatment of Acute Bipolar Depression
Deeks, E. D., & Keating, G. M. (2008) · Drugs · doi:10.2165/00003495-200868080-00008 · Cited by 23
Safety and Efficacy of Quetiapine in Bipolar Depression
Bogart, G. T., & Chavez, B. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m193 · Cited by 26
Class effect of pharmacotherapy in bipolar disorder: fact or misbelief?
Fountoulakis, K. Ν., Gonda, X., Vieta, E., & Rihmer, Z. (2011) · Annals of General Psychiatry · doi:10.1186/1744-859x-10-8 · Cited by 23
A systematic review of the evidence for the treatment of acute depression in bipolar I disorder
Cerullo, M. A., & Strakowski, S. M. (2013) · CNS Spectrums · doi:10.1017/s1092852913000102 · Cited by 21
Lamotrigine (Lamictal IR) for the treatment of bipolar disorder
Bowden, C. L., & Singh, V. K. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.741590 · Cited by 20
The Contemporary Face of Bipolar Illness:Complex Diagnostic and Therapeutic Challenges
Fountoulakis, K. Ν. (2008) · CNS Spectrums · doi:10.1017/s1092852900013894 · Cited by 23
Gao, K., Yuan, C., Wu, R., Chen, J., Wang, Z., Fang, Y., & Calabrese, J. R. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-014-1534-0 · Cited by 19
Psychosis: Atypical limbic epilepsy versus limbic hyperexcitability with onset at puberty?
Sharp, F. R., & Hendren, R. L. (2007) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2007.02.014 · Cited by 24
Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients
Houston, J., Fijal, B. A., Heinloth, A. N., & Adams, D. H. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2009.06.014 · Cited by 17
Self-citationBobo, W. V., EPSTEIN, R. A., & Shelton, R. C. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1082 · Cited by 16
Schoenknecht, P., Traenkner, & Sander (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s37126 · Cited by 16
Metadata
- Authors
- Brown, E. B., McElroy, S. L., Keck, P. E., Deldar, A., Adams, D. H., Tohen, M., & Williamson, D. J.
- Affiliations
- Eli Lilly (United States) (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2006-07-15
- Volume
- 67
- Issue
- 07
- Pages
- 1025-1033
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2011797837
- Cited by
- 244
- References
- 0
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 32 · 2019: 4 · 2018: 3 · 2017: 4 · 2016: 32 · 2015: 9 · 2014: 15 · 2013: 11 · 2012: 10
- FWCI
- 13.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- bipolar I depression, olanzapine-fluoxetine combination, lamotrigine, atypical antipsychotics, antidepressant efficacy, treatment response time, adverse events, weight gain, tolerability, mood stabilizers, Young Mania Rating Scale, Montgomery-Asberg Depression Rating Scale, clinical global impression
- MeSH terms
- Olanzapine, Lamotrigine, Adult, Anticonvulsants, Benzodiazepines, Bipolar Disorder, Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Fluoxetine, Humans, Male, Psychiatric Status Rating Scales, Severity of Illness Index, Antipsychotic Agents, Triazines, Self-Injurious Behavior, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.